Morning Trend | TEDA BIOMEDICAL retreats from high levels, is the biotech heat switching focus?
On November 26th, TEDA BIOMEDICAL showed extremely cautious performance during the trading session. The risk-averse nature of funds in the biotechnology sector has increased, and the market style continues to switch. The company has no new announcements, and its stock price has been continuously adjusting downward from its high, with active trading being relatively weak. Funds further flowed out of the market, creating a heightened atmosphere of wait-and-see. From a macro perspective, the biopharmaceutical sector is currently in a high-level pullback phase, with most funds actively avoiding volatile sectors and shifting towards low-beta defensive areas such as consumption and finance. The MACD daily technical signals have weakened, and short-term moving averages have been consistently breached, indicating significant fluctuations in market sentiment. The enthusiasm for the sector is cooling down rapidly, with frequent rotations of new themes. There are no signs of a stop in the high-level pullback, and investors are focusing on key support levels and intraday trading performance. Sudden inflows of funds or news regarding new drug policies remain short-term focal points. Overall, the rhythm should not underestimate the risk exposure brought about by sector switching
On November 26th, TEDA BIOMEDICAL showed extremely cautious performance during the trading session. The risk-averse nature of funds in the biotechnology sector has increased, and the market style continues to switch. The company has no new announcements, and its stock price has been continuously adjusting downward from its high, with active trading being relatively weak. Funds further flowed out of the market, creating a heightened atmosphere of wait-and-see.
From a macro perspective, the biopharmaceutical sector is currently in a high-level pullback phase, with most funds actively avoiding volatile tracks and shifting towards low-beta defensive areas such as consumption and finance. The MACD daily technical signals have weakened, and short-term moving averages have been consistently breached, indicating significant fluctuations in market sentiment. The heat of the sector is cooling down rapidly, with frequent rotations of new themes.
There are no signals yet indicating a stop to the high-level pullback, and investors are focusing on key support levels and intraday trading performance. Sudden inflows of funds or news regarding new drug policies remain short-term focal points. Overall, the rhythm should not underestimate the risk exposure brought about by sector switching
